Using tversky similarity searches for core hopping: Finding the needles in the haystack

Journal of Chemical Information and Modeling

Volumn 49, Issue 6, 2009, Pages 1514-1524

  Senger, Stefan ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SCAFFOLDS;

BIOLOGICAL TARGETS; CENTRAL CORE; FALSE POSITIVE; POST PROCESS; SCAFFOLD HOPPING; SIMILARITY SEARCH; STRUCTURAL DIFFERENCES; TARGET MOLECULE;

MOLECULES;

BRADYKININ; CANNABINOID 1 RECEPTOR; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5;

ARTICLE; DRUG ANTAGONISM; DRUG SCREENING; FACTUAL DATABASE; HUMAN; METABOLISM; METHODOLOGY;

BRADYKININ; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; HUMANS; KV1.5 POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKERS; RECEPTOR, CANNABINOID, CB1;

EID: 67650178286     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci900092y     Document Type: Article

References (48)

1. Böhm, H.-J.; Flohr, A.; Stahl, M. Scaffold Hopping. Drug Discovery Today Technol. 2004, 1, 217-224.
2. Schneider, G.; Schneider, P.; Renner, S. Scaffold-Hopping: How Far Can You Jump? QSAR Comb. Sci. 2006, 25, 1162-1171.
3. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. "Scaffold- hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. Angew. Chem., Int. Ed. 1999, 38, 2894-2896.
4. Green, D. V. S. Virtual Screening of Virtual Libraries. Prog. Med. Chem. 2003, 41, 61-97.
5. Shelley, M.; Frye, L. L.; Sherman, B. W.; Rao, S. N.; Beard, H.; Mozziconacci, J.-C.; Shenkin, P. S. New Approach to Lead Optimization and Core Hopping., 234th ACS National Meeting, Boston, MA, August 19-23, 2007; American Chemical Society: Washington, DC, 2007; COMP-406.
6. 1 Receptor Antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 2385-2388.
7. 1 Receptor Antagonists. J. Med. Chem. 2007, 50, 272-282.
8. Kuduk, S. D.; Wood, M. R.; Bock, M. G. PCT Int. Appl. WO 2004/019868, 2004.
9. Daylight Chemical Information Systems. http://www.daylight.com (accessed April 23, 2009).
10. Where not otherwise noted, all Daylight fingerprints used in this study have a length of 1024 bits and have been calculated using a minimal path length of zero and a maximum path length of 7.
11. Tversky, A. Features of Similarity. Psychol. Rev. 1997, 84, 327-352.
12. Leach, A. R.; Gillet, V. J. An Introduction to Chemoinformatics; Kluwer Academic Publishers: Dordrecht, The Netherlands, 2003.
13. 11 for two molecules A and B is calculated as follows: S Tversky = c/ (R(a-c) + (b-c) + c). For binary data, a is defined as the number of bits set to "1" in molecule A. Similarly, b is defined as the number of bits set to "1" in molecule B. c is the number of bits set to "1" in both A and B. R and are user-defined constants.
14. Rupp, M.; Schneider, P.; Schneider, G. Distance Phenomena in High-Dimensional Chemical Descriptor Spaces: Consequences for Similarity-Based Approaches J. Comput. Chem. [Online early access]. DOI:10.1002/jcc.21218 Published Online: March 5, 2009.
15. 1 Receptor Antagonists. J. Med. Chem. 2006, 49, 1231-1234.
16. Babu, Y. S.; Rowland, R. S.; Chand, P.; Kotian, P. L.; El-Kattan, Y.; Niwas, S. U.S. Patent 6,699,994, 2004.
17. Wagener, M.; Lommerse, J. P. M. The Quest for Bioisosteric Replacements. J. Chem. Inf. Model. 2006, 46, 677-685.
18. Leach, A. R.; Green, D. V. S.; Hann, M. M.; Harper, G.; Whittington, A. R. SIV: A Synergistic Approach to the Analysis of High-Throughput Screening Data; 221st ACS National Meeting, San Diego, CA, April 1-5, 2001; American Chemical Society: Washington, DC, 2001; ClNF-080.
19. CORUS is an acronym and stands for core replacement utility script.
20. Aureus Pharma. http://www.aureus-pharma.com (accessed April 23, 2009).
21. Arsenic has been chosen as a "dummy atom" in the fragmentation algorithm since it normally does not occur in the molecules we are interested in and at the same time is one of the view elements that can be a member of an aromatic ring in a SMILES string. The charge of the arsenic atom is set according to the valency of the atomic position.
22. There are two parameters in the fragmentation algorithm that determine how many mutants are considered for further analysis. The first parameter is multiplied with the Tversky similarity value for the top match and the result is used as threshold. For this study, the parameter was set to 0.95. If for example, the maximum Tversky similarity value is 1.0, this would mean that all mutants with a Tversky similarity value of 0.95 or more will be considered in the following steps. However, to avoid a case where a large number of mutants will have to be looked at, we have also introduced a second parameter that restricts the number of mutants that will be considered (and that in this study was set to 10).
23. Bayada, D. M.; Simpson, R. W.; Johnson, A. P.; Laurenco, C. An algorithm for the multiple common subgraph problem. J. Chem. Inf. Comput. Sci. 1992, 32, 680-685.
24. TIBCO. http://spotfire.tibco.com (accessed April 23, 2009).
25. Wood, M. R.; Su, D.-S.; Wai, J. M.-C. U.S. Patent 2006/0173023, 2006.
26. Gauthier, J. Y.; Leblanc, Y.; Black, W. C.; Chan, C.-C.; Cromlish, W. A.; Gordon, R.; Kennedy, B. P.; Lau, C. K.; Léger, S.; Wang, Z.; Ethier, D.; Guay, J.; Mancini, J.; Riendeau, D.; Tagari, P.; Vickers, P.; Wong, E.; Xu, L.; Prasit, P. Synthesis and Biological Evaluation of 2,3-Diarylthiophenes As Selective COX-2 Inhibitors. Part II: Replacing the Heterocycle. Bioorg. Med. Chem. Lett. 1996, 6, 87-92.
27. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Léger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Thérien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The Discovery of Rofecoxib [MK 966, VIOXX, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], An Orally Active Clyclooxygenase-2 Inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
28. Friesen, R. W.; Brideau, C.; Chan, C. C.; Charleson, S.; Deschênes, D.; Dubé, D.; Ethier, D.; Fortin, R.; Gauthier, J. Y.; Girard, Y.; Gordon, R.; Greig, G. M.; Riendeau, D.; Savoie, C.; Wang, Z.; Wong, E.; Visco, D.; Xu, L. J.; Young, R. N. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and Orally Active Cyclooxygenase-2 Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2777-2782.
29. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
30. Talley, J. J.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Rodgers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
31. Lohray, B. B.; Lohray, V. B.; Jain, M. R.; Patel, G. D.; Pingali, H. PCT Int. Appl. WO 2003/087062, 2003.
32. Puig Duran, C.; Feixas Gras, J.; Jimenez Mayorga, J. M.; Crespo Crespo, M. I. PCT Int. Appl. WO 1999/14205 1999.
33. Reddy, M. V. R.; Bell, S. C. PCT Int. Appl. WO 2003/024958, 2003.
34. Rinaldi-Carmona, M.; Barth, F.; Héaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Néliat, G.; Caput, D.; Ferrara, P.; Soubrié, P.; Brelière, J. C.; Le Fur, G. SR141716A, A Potent and Selective Antagonist of the Brain Cannabinoid Receptor. FEBS Lett. 1994, 350, 240-244.
35. 1Cannabinoid Receptor Antagonists. Drug Discovery Today 2005, 10, 693-702.
36. Berggren, A. I. K.; Bostrom, S. J.; Cheng, L.; Elebring, S. T.; Greasley, P.; Nagard, M.; Wilstermann, J. M.; Terricabras, E. PCT Int. Appl. WO 2004/058249, 2004.
37. Ellsworth, B. A.; Wang, Y.; Zhu, Y.; Pendri, A.; Gerritz, S. W.; Sun, C.; Carson, K. E.; Kang, L.; Baska, R. A.; Yang, Y.; Huang, Q.; Burford, N. T.; Cullen, M. J.; Johnghar, S.; Behnia, K.; Pelleymounter, M. A.; Washburn, W. N.; Ewing, W. R. Discovery of pyrazine carboxamide CB1 antagonists: The introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series. Bioorg. Med. Chem. Lett. 2007, 17, 3978-3982.
38. Toupence, R. B.; Debenham, J. S.; Goulet, M. T.; Madsen-Duggan, C. B.; Walsh, T. F.; Shah, S. K. PCT Int. Appl. WO 2004/012671, 2004.
39. Moritani, Y.; Shirai, K.; Oi, M. PCT Int. Appl. WO 2007/046548, 2007.
40. Alanine, A.; Bleicher, K.; Guba, W.; Haap, W.; Kube, D.; Luebbers, T.; Plancher, J.-M.; Roche, O.; Rogers-Evans, M.; Schneider, G.; Zuegge, J. U.S. Patent 2004/0142922, 2004.
41. Lange, J. H. M.; Kruse, C. G.; van Stuivenberg, H. H. U.S. Patent 2005/0171179, 2005.
42. Carpino, P. A.; Dow, R. L. U.S. Patent Appl. US 2004/02114855, 2004.
43. Schneider, G.; Clément-Chomienne, O.; Hilfiger, L.; Schneider, P.; Kirsch, S.; Böhm, H.-J.; Neidhart, W. Virtual Screening for Bioactive Molecules by Evolutionary De Novo Design. Angew. Chem., Int. Ed. 2000, 39, 4130-4133.
44. Castle, N. A.; Hollinshead, S. P.; Hughes, P. F.; Mendoza, J. S.; Wilson, J. W.; Amato, G.; Beaudoin, S.; Gross, M.; McNaughton-Smith, G. PCT Int. Appl. WO 1998/04521, 1998.
45. */R = Et.
46. Gross, M.; Castle, N. A. Int. PCT Appl. WO 1999/37607, 1999.
47. Brendel, J.; Pirard, B.; Peukert, S.; Kleeman, H.-W.; Hemmerle, H. U.S. Patent Appl. US 2007/0117807, 2007.
48. Senger, S.; Leach, A. R. SAR Knowledge Bases in Drug Discovery. Ann. Rep. Comput. Chem. 2008, 4, 203-216.